vorinostat has been researched along with Head and Neck Neoplasms in 15 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat was administered at the assigned dosage level (100-400 mg, three times weekly) in a standard 3 + 3 dose escalation design." | 2.90 | A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. ( Agrawal, A; Baiocchi, R; Blakaj, D; Carrau, R; Diavolitsis, V; Grecula, J; Kang, S; Kumar, B; Kumar, P; Old, MO; Ozer, E; Palettas, M; Pan, Q; Rocco, J; Savvides, P; Teknos, TN; Wei, L, 2019) |
| "Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients." | 2.73 | Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. ( Blumenschein, GR; Chen, C; Chiao, JH; Frankel, SR; Kies, MS; Kumar, AJ; Lu, C; Papadimitrakopoulou, VA; Ricker, JL, 2008) |
| " Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors." | 1.40 | Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. ( Johnson, DE; Kirk, CJ; Zang, Y, 2014) |
| "Head and neck squamous cell carcinoma cell lines, human keratinocyte and HNSCC xenograft models were treated with histone deacetylase inhibitors (HDACIs) and new generation PI3K and dual PI3K-mTOR inhibitors either alone or in combination." | 1.38 | Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. ( Cameron, S; Dahler, A; de Long, LM; Endo-Munoz, L; Erlich, RB; Guminski, A; Hazar-Rethinam, M; Kherrouche, Z; Rickwood, D; Saunders, NA; Wooley, K, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zagni, C | 1 |
| Pistarà, V | 1 |
| Oliveira, LA | 1 |
| Castilho, RM | 1 |
| Romeo, G | 1 |
| Chiacchio, U | 1 |
| Rescifina, A | 1 |
| Alves Avelar, LA | 1 |
| Schrenk, C | 1 |
| Sönnichsen, M | 1 |
| Hamacher, A | 1 |
| Hansen, FK | 1 |
| Schliehe-Diecks, J | 1 |
| Borkhardt, A | 1 |
| Bhatia, S | 1 |
| Kassack, MU | 1 |
| Kurz, T | 1 |
| Pan, C | 3 |
| Wu, QV | 4 |
| Voutsinas, J | 4 |
| Houlton, JJ | 3 |
| Barber, B | 3 |
| Futran, N | 3 |
| Laramore, GE | 3 |
| Liao, JJ | 3 |
| Parvathaneni, U | 3 |
| Martins, RG | 3 |
| Fromm, JR | 4 |
| Rodriguez, CP | 4 |
| Akhlaq, R | 1 |
| Khan, T | 1 |
| Ahmed, T | 1 |
| Musharraf, SG | 1 |
| Ali, A | 1 |
| Jiang, X | 1 |
| Pillarisetty, VG | 1 |
| Lee, SM | 1 |
| Santana-Davila, R | 1 |
| Goulart, B | 1 |
| Baik, CS | 1 |
| Chow, LQM | 1 |
| Eaton, K | 1 |
| Martins, R | 1 |
| Tanaka, N | 1 |
| Patel, AA | 1 |
| Tang, L | 1 |
| Silver, NL | 1 |
| Lindemann, A | 1 |
| Takahashi, H | 1 |
| Jaksik, R | 1 |
| Rao, X | 1 |
| Kalu, NN | 1 |
| Chen, TC | 1 |
| Wang, J | 2 |
| Frederick, MJ | 1 |
| Johnson, F | 1 |
| Gleber-Netto, FO | 1 |
| Fu, S | 1 |
| Kimmel, M | 1 |
| Hittelman, WN | 1 |
| Pickering, CR | 1 |
| Myers, JN | 1 |
| Osman, AA | 1 |
| Teknos, TN | 2 |
| Grecula, J | 1 |
| Agrawal, A | 1 |
| Old, MO | 1 |
| Ozer, E | 1 |
| Carrau, R | 1 |
| Kang, S | 1 |
| Rocco, J | 1 |
| Blakaj, D | 1 |
| Diavolitsis, V | 1 |
| Kumar, B | 1 |
| Kumar, P | 1 |
| Pan, Q | 2 |
| Palettas, M | 1 |
| Wei, L | 1 |
| Baiocchi, R | 1 |
| Savvides, P | 1 |
| Zang, Y | 1 |
| Kirk, CJ | 1 |
| Johnson, DE | 1 |
| Datta, J | 1 |
| Islam, M | 1 |
| Dutta, S | 1 |
| Roy, S | 1 |
| Shim, SH | 1 |
| Lee, CT | 1 |
| Lee, JJ | 1 |
| Kim, SY | 1 |
| Hah, JH | 1 |
| Heo, DS | 1 |
| Sung, MW | 1 |
| Bruzzese, F | 1 |
| Leone, A | 1 |
| Rocco, M | 1 |
| Carbone, C | 1 |
| Piro, G | 1 |
| Caraglia, M | 1 |
| Di Gennaro, E | 1 |
| Budillon, A | 1 |
| Erlich, RB | 1 |
| Kherrouche, Z | 1 |
| Rickwood, D | 1 |
| Endo-Munoz, L | 1 |
| Cameron, S | 1 |
| Dahler, A | 1 |
| Hazar-Rethinam, M | 1 |
| de Long, LM | 1 |
| Wooley, K | 1 |
| Guminski, A | 1 |
| Saunders, NA | 1 |
| Zhang, Y | 1 |
| Jung, M | 2 |
| Dritschilo, A | 1 |
| Blumenschein, GR | 1 |
| Kies, MS | 1 |
| Papadimitrakopoulou, VA | 1 |
| Lu, C | 1 |
| Kumar, AJ | 1 |
| Ricker, JL | 1 |
| Chiao, JH | 1 |
| Chen, C | 1 |
| Frankel, SR | 1 |
| Gillenwater, AM | 1 |
| Zhong, M | 1 |
| Lotan, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies[NCT02538510] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2015-10-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Kaplan Meier methods will be used to estimate progression free survival. (NCT02538510)
Timeframe: Up to 2 years
| Intervention | Months (Mean) |
|---|---|
| Head and Neck Squamous Cell Carcinoma | 12.6 |
| Salivary Gland Carcinoma | 14.0 |
Toxicities will be summarized as the number and percentage of patients with each type of toxicity, per Criteria for Adverse Events version 4.0 (NCT02538510)
Timeframe: Up to 30 days after the completion of study treatment
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiency | ALT increase | Anorexia | Arthiritis | AST increase | Cough | Increased Creatinine | Dermatitis | Diarrhea | Fever with leukocytosis | Fatigue | Hyponatremia | Hypothyroidism | Colitis and Ileitis | Malaise | Nausea | Nephritis | Pneumonitis | Neuritis | Tracheitis/Epiglottitis | Vomiting | |
| Head and Neck Squamous Cell Carcinoma | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| Salivary Gland Carcinoma | 1 | 1 | 1 | 1 | 1 | 0 | 5 | 0 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 2 |
Radiologic assessments of measurable disease will be performed using radiographic imaging. RECIST 1.1 and immune response criteria will be used to assess response to therapy. Responses will be summarized as frequencies and percentages. (NCT02538510)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| partial response | stable disease | progressive disease | |
| Head and Neck Squamous Cell | 8 | 8 | 5 |
| Salivary Gland Carcinoma | 4 | 13 | 6 |
4 trials available for vorinostat and Head and Neck Neoplasms
11 other studies available for vorinostat and Head and Neck Neoplasms
| Article | Year |
|---|---|
Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Proliferation; Dose-Response Relationship, Dru | 2017 |
Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Drug Synergism; Epigenomics; Head and Neck Neoplasms; Histone Deac | 2021 |
PX-12 synergistically enhances the therapeutic efficacy of vorinostat under hypoxic tumor microenvironment in oral squamous cell carcinoma in vitro.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Disulfides; Head and Neck Neoplasms; Histone Deacetylase | 2023 |
Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferat | 2017 |
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, S | 2014 |
Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Genes, Tumor | 2016 |
A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC.
Topics: Adenoviridae; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Coxsackie and Adeno | 2010 |
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Li | 2011 |
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Head and | 2012 |
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Depsipeptides; Dos | 2004 |
Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
Topics: Acetylation; Apoptosis; Carcinoma, Squamous Cell; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Pr | 2007 |